SEC Comment Letter for RELMADA THERAPEUTICS, INC. (RLMD) (CIK 0001553643) (RLMD) — Feb 8, 2019
RELMADA THERAPEUTICS, INC. (RLMD) (CIK 0001553643)
Date: Feb. 8, 2019 · CIK: 0001553643 · Accession: 0000000000-19-001659
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229258
Letter
February 7, 2019 Sergio Traversa Chief Executive Officer RELMADA THERAPEUTICS, INC. 880 Third Avenue 12th Floor New York, NY 10017 Re:RELMADA THERAPEUTICS, INC. Registration Statement on Form S-1 Filed January 14, 2019 File No. 333-229258 Dear Mr. Traversa: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Todd Schiffman at 202-551-3491 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
February 7, 2019
Sergio Traversa
Chief Executive Officer
RELMADA THERAPEUTICS, INC.
880 Third Avenue
12th Floor
New York, NY 10017
Re:RELMADA THERAPEUTICS, INC.
Registration Statement on Form S-1
Filed January 14, 2019
File No. 333-229258
Dear Mr. Traversa:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Todd Schiffman at 202-551-3491 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance